We found that TPX2-overexpressing CD8 + T cells significantly restricted tumor growth, and anti-PD-1 therapy synergistically inhibited tumor growth, while TPX2-depleted CD8 + T cells did not delay tumor growth and showed a poor response to anti-PD-1 therapy (Fig. 5C). Here, TPX2 is linked to neoplasm.